Vanda Pharmaceuticals' VQW-765 fails primary endpoint in Phase III social anxiety disorder study; program on hold

Vanda Pharmaceuticals' Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint. The drug was safe and well-tolerated. Vanda said it is putting the program on hold.

Detected & updated continuously · Source: Nebula